Loading...
•
Jun 30, 2022
Voyager Therapeutics Q2 2022 Earnings Report
Voyager Therapeutics prioritized its pipeline and reported financial results for the second quarter of 2022.
Key Takeaways
Voyager Therapeutics reported a net loss of $19.1 million for the second quarter of 2022, compared to a net loss of $30.1 million for the same period in 2021. The company's prioritized pipeline focuses on programs with efficient paths to human proof of biology, including GBA1 gene replacement for Parkinson's disease, SOD1 gene silencing for ALS, and a tau antibody program for Alzheimer's disease.
Voyager prioritized pipeline programs for Alzheimer's disease, GBA1 Parkinson's disease, and SOD1-ALS.
The company is targeting development candidate selection for priority programs in 2022 and H1 2023.
Cross species transduction for multiple capsids and characterization of the receptor for a leading capsid support human translation potential of TRACER capsids.
Voyager expects to maintain cash runway into 2024.
Revenue by Segment
Forward Guidance
Voyager expects that its cash, cash equivalents, and marketable securities, together with amounts expected to be received as reimbursement for development costs under the Neurocrine collaboration, will be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...